FDA-cleared profile

EFAI RTSuite CT HN-Segmentation System

Ever Fortune.AI Co., Ltd. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: EFAI RTSuite CT HN-Segmentation System automatically delineates head-and-neck organs at risk on adult non-contrast CT images to support radiation-treatment workflows; initial contours are transferred to a DICOM-compliant treatment-planning system for professional review and editing.

Clinical role
Radiotherapy contouring, treatment planning, adaptation, or treatment-session support under professional review.
Images and patients
Radiotherapy Planning Imaging · Head and neck organs at risk
Key limitation
Keep in mind: Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: EFAI RTSuite CT HN-Segmentation System automatically delineates head-and-neck organs at risk on adult non-contrast CT images to support radiation-treatment workflows; initial contours are transferred to a DICOM-compliant treatment-planning system for professional review and editing.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Head and neck organs at risk Input: Supported CT or MR images, structures, prescriptions, plans, registrations, and treatment-session data.
  • Who uses it?Intended users: Qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists.
  • What does the software produce?Output: Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.
  • What is its most important limitation?Key limitation: Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.

Clinical takeaway. Clinical role: EFAI RTSuite CT HN-Segmentation System automatically delineates head-and-neck organs at risk on adult non-contrast CT images to support radiation-treatment workflows; initial contours are transferred to a DICOM-compliant treatment-planning system for professional review and editing.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation testing and a non-inferiority standalone performance test comparing the mean Dice coefficient of automatically generated head and neck OAR contours with that of the predicate device; it states the device was non-inferior to the predicate by at least a non-inferiority limit of 0.1 Dice, described as the largest clinically acceptable difference based on previous studies. No measured Dice values or test dataset size are given. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
EFAI RTSuite CT HN-Segmentation System automatically delineates head-and-neck organs at risk on adult non-contrast CT images to support radiation-treatment workflows; initial contours are transferred to a DICOM-compliant treatment-planning system for professional review and editing.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Radiotherapy contouring, treatment planning, adaptation, or treatment-session support under professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported CT or MR images, structures, prescriptions, plans, registrations, and treatment-session data.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation-oncology departments using compatible planning, imaging, and treatment-delivery systems.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports software verification and validation testing and a non-inferiority standalone performance test comparing the mean Dice coefficient of automatically generated head and neck OAR contours with that of the predicate device; it states the device was non-inferior to the predicate by at least a non-inferiority limit of 0.1 Dice, described as the largest clinically acceptable difference based on previous studies. No measured Dice values or test dataset size are given. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Performance of the EFAI HNSeg v1.0 has been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing." … "To establish the contour performance of EFAI HNSeg, a non-inferiority standalone performance test was performed. This non-inferiority test compared the mean Dice coefficient of the automatically generated head and neck OAR contours for EFAI HNSeg against that of the predicate device". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports software verification and validation testing and a non-inferiority standalone performance test comparing the mean Dice coefficient of automatically generated head and neck OAR contours with that of the predicate device; it states the device was non-inferior to the predicate by at least a non-inferiority limit of 0.1 Dice, described as the largest clinically acceptable difference based on previous studies. No measured Dice values or test dataset size are given. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Performance of the EFAI HNSeg v1.0 has been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing." … "To establish the contour performance of EFAI HNSeg, a non-inferiority standalone performance test was performed. This non-inferiority test compared the mean Dice coefficient of the automatically generated head and neck OAR contours for EFAI HNSeg against that of the predicate device". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K220264 FDA evidence package for EFAI RTSuite CT HN-Segmentation System

  • DesignFDA 510(k) substantial-equivalence decision evidence and product verification described in the exact submission.
  • PopulationHead and neck organs at risk
  • Scopeexact submission
  • Tested versionEFAI RTSuite CT HN-Segmentation System configuration described in K220264
  • IndependenceSponsor or vendor study

K220264

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K220264 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported CT or MR images, structures, prescriptions, plans, registrations, and treatment-session data.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K220264: EFAI RTSuite CT HN-Segmentation System

  2. Routing

    Source context, not route validation: The exact FDA package describes DICOM CT input and DICOM or RTSTRUCT organ-at-risk output to a DICOM-compliant treatment-planning system; verify exact local compatibility.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, and archive behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K220264: EFAI RTSuite CT HN-Segmentation System

  3. AI processing

    Source context, not route validation: The exact FDA package describes a specialized server on a local network for the EFAI HN-Segmentation release; verify current topology, service responsibility, and site configuration locally.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K220264: EFAI RTSuite CT HN-Segmentation System

  4. Returned objects

    Source context, not route validation: Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K220264: EFAI RTSuite CT HN-Segmentation System

  5. Viewer/worklist/report

    Unresolved route: Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K220264: EFAI RTSuite CT HN-Segmentation System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes a specialized server on a local network for the EFAI HN-Segmentation release; verify current topology, service responsibility, and site configuration locally.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, and site configuration remain separate evidence.

Integration
The exact FDA package describes DICOM CT input and DICOM or RTSTRUCT organ-at-risk output to a DICOM-compliant treatment-planning system; verify exact local compatibility.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, and archive behavior still require acceptance testing.

Security
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.

Training
Only qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K220264 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.
  • Exact FDA submission
  • Checked 2026-09-04

Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K220264 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact FDA package describes a specialized server on a local network for the EFAI HN-Segmentation release; verify current topology, service responsibility, and site configuration locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact FDA package describes DICOM CT input and DICOM or RTSTRUCT organ-at-risk output to a DICOM-compliant treatment-planning system; verify exact local compatibility.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K220264 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. radiotherapy planning or image-processing software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220264
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Head and neck organs at risk
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-04-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K220264: EFAI RTSuite CT HN-Segmentation System

    U.S. Food and Drug Administration - Published 2022-04-28 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Ever Fortune.AI: Information Security Policy (ISO 27001 / ISO 27701)

    Ever Fortune.AI - Accessed 2026-10-27

    Scope: security

Research history

  1. K220264 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251351

AccuContour 4.0

Manteia Technologies Co., Ltd.

Authorized purpose: AccuContour 4.0 uses deep-learning contours to support segmentation of organs at risk on CT images for radiation-treatment planning, evaluation, and adaptation; qualified professionals review and may edit the contours.

Modality
Radiotherapy Planning Imaging
Anatomy
Head and neck, thorax, abdomen, and pelvis organs at risk
Decision
2026-01-23
FDA-cleared K250035

Contour ProtégéAI+

MIM Software Inc.

Authorized purpose: Contour ProtégéAI+ automatically creates contours on CT and T2 MR DICOM images as an accessory to MIM software for quantitative analysis, adaptive therapy, transfer, and archive; users must review and edit contours, and the device is not intended to detect or contour lesions.

Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomical regions; prostate, seminal vesicles, and urethra on T2 MR
Decision
2025-02-03
FDA-cleared K232928

DeepContour (V1.0)

Wisdom Technologies., Inc.

Authorized purpose: DeepContour uses deep-learning CT processing to generate editable organ contours and RTSTRUCT objects for selected adult radiation-treatment planning workflows, with quantitative statistics, registration, and three-dimensional visualization; it does not contour tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2024-05-07
FDA-cleared K231765

Contour ProtégéAI

MIM Software Inc.

Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segments structures across CT locations, and segments the prostate, seminal vesicles, and urethra on T2-weighted MR images.

Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR
Decision
2023-11-08

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history